Search

Search Constraints

You searched for: Author/Creator Petit, T.

Search Results

1. 1320 Eribulin mesylate in metastatic breast cancer, a focus on safety and efficacy in elderly patients. Results from the EVHALAVEN multicentric retrospective cohort. (September 2015)

2. 1865 Activity and toxicity profile of eribulin mesylate in heavily pretreated metastatic breast cancer: An observational study (EVHALAVEN). (September 2015)

4. [OP.1B.01] VITAMIN K DEPENDENT PROTECTION OF RENAL FUNCTION IN MULTI-ETHNIC POPULATION STUDIES. (September 2016)

5. [OP.7C.07] DIASTOLIC LEFT VENTRICULAR FUNCTION IN RELATION TO COLLAGEN-SPECIFIC URINARY AND SERUM COLLAGEN BIOMARKERS IN A GENERAL POPULATION. (September 2016)

6. [PP.07.05] PLATELET ENDOTHELIAL AGGREGATION RECEPTOR 1 IS NOT A SUSCEPTIBILITY GENE FOR CARDIOVASCULAR DISEASE IN THE GENERAL POPULATION. (September 2016)

7. A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study. (24th February 2016)

9. CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database. (February 2020)

10. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. (18th October 2016)